Pathophysiological aspects of chronic heart failure

Česká verzia

Authors: Andrej Dukát ¹; Juraj Payer ¹; Ján Gajdošík ²; Valentín Szabó ²; Fedor Šimko ³
Authors place of work: V. interná klinika LF UK a UNB, Nemocnica Ružinov, Bratislava ¹; Neštátna ambulancia pre dospelých v Nových Zámkoch ²; Ústav patologickej fyziológie LF UK v Bratislave ³
Published in the journal: Forum Diab 2020; 9(2): 95-97
Category:

Summary

Chronic heart failure represents nowadays one of the most severe problems in cardiology and in all world´s health care systems. Syndrome has not only high prevalence, but has worse prognosis for the patient with the disease. In case of severe heart failure only half of the pa-tients will be living more, than one year. Prevalence of the heart failure despite sucesses in the treatment is increasing for improved diagnosis and population aging in many countries in the world. It is expecting, that the prevalence of this disease will increase to 3 % in the next short period of five years.

Keywords:

heart failure – pathophysiology

Zdroje

Braunwald E. The management of heart failure: the past, the present, and the future. Circ Heart Fail 2008; 1(1): 58–62. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCHEARTFAILURE.107.752162>.

Packer M. The impossible task of developing a new treatment for heart failure. J Card Fail 2002; 8(4): 193–196. Dostupné z DOI: <http://dx.doi.org/10.1054/jcaf.2002.128001>.

Šimko F. Patofyziológia. In: Goncalvesová E et al (eds). Zlyhávanie srdca. ProLitera: Bratislava 2015: 71–82. ISBN 978–80–89668–03–8.

Goncalvesová E. Srdcové zlyhávanie a diabetes mellitus. Nebezpečné spojenie. Cardiol Lett 2020; 29(1): 9–16.

McMurray J, Cohen-Solal A, Dietz R et al. Clinical Research Initiative in Heart failure. Practical recommendations for the use of ACE-inhibitors, beta-blockers and spironolactone in heart failure: putting guidelines into practice. Eur J Heart Fail 2001; 3(4): 495–502. Dostupné z DOI: <http://dx.doi.org/10.1016/s1388–9842(01)00173–8>.

McMurray J. Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances. Eur J Heart Fail 2015; 17(3): 242–247. Dostupné z DOI: <http://dx.doi.org/10.1002/ejhf.250>.

McMurray J, Packer M, Desai AS et al. [PARADIGHM-HF Investigators and Committees]. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371(11): 993–1004. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1409077>.

Packer M, McMurray J, Desai AS et al. [PARADIGHM-HF Investigators and Coordinators]. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 2015; 131(1): 54–61. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.114.013748>.

Dzau VJ. Autocrine and paracrine mechanisms in the pathophysiology of heart failure. Am J Cardiol 1992; 70(10): 4C-11C. Dostupné z DOI: <http://dx.doi.org/.1016/0002–9149(92)91352–5>.

Šimko F. Patomechanizmus zlyhania srdca. In: Hulín I et al (eds). Patofyziológia. SAP: Bratislava 2002: 520–530. ISBN 9788080950439.

Goncalvesová E. Diabetes mellitus a srdcové zlyhávanie: trendy v liečbe pre rok 2019. Forum Diab 2019; 8(2): 60.

Murín J, Bulas J, Wawruch M. Diabetická kardiomyopatia a srdcové zlyhávanie. Forum Diab 2019; 8(3): 165–169.

Šimko F. Zlyhanie srdca. In: Kiňová S, Hulín I (eds). Interná medicína. ProLitera: Bratislava 2013: 265–282. ISBN 9788097025397.

Goncalvesová E. Diabetes mellitus a srdcové zlyhávanie – osudová príťažlivosť. Forum Diab 2019; 8(2): 99–105.

Šimko F, Šimko J, Fábryova M. ACE-inhibition and angiotensin receptor blockers in chronic heart failure: pathophysiological consideration of the unresolved battle. Cardiovasc Drugs Ther 2003; 17(3): 287–290. Dostupné z DOI: <http://dx.doi.org/10.1023/a:1026215712983>.